France manufacturing production change: pharmaceuticals
France manufacturing production change: pharmaceuticals stood at 1.94 Balance of opinion in Sep 2026, according to Banque de France – Webstat (webstat.banque-france.fr). It is one of the indicators in the Banque de France business surveys table (Value · Monthly), with a complete series running from Jan 1996 to Sep 2026. The complete series with an interactive chart, free to download.
This indicator in the Banque de France business surveys table
| Indicator | 09-2026 | 08-2026 | 07-2026 | 06-2026 | 05-2026 | 04-2026 | 03-2026 | 02-2026 | 01-2026 | 12-2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Production, change on previous month | |||||||||||
| Pharmaceuticals | 1.94 | 0.27 | 3.22 | 1.1 | 3.6 | -0.29 | 11.58 | -4.27 | -5.04 | 5.53 | |
| Rubber, plastics and other non-metallic mineral products | -1.12 | 6.91 | -4.5 | 1.59 | -2.04 | 9.43 | -0.33 | 1.29 | -4.04 | 4.4 |
Understanding france manufacturing production change: pharmaceuticals
Executive feedback collected from active pharmaceutical formulation laboratories, biological preparation facilities, and medicinal chemical synthesis plants underpins this specialized industrial gauge. The tabulation zeroes in exclusively on therapeutic product creation, omitting retail apothecary distribution, wholesale medical logistics, and basic research institutions. Survey participants report whether their production volumes expanded or contracted relative to the preceding monthly interval.
Analyzing this health sector indicator requires awareness of regulatory batch approvals and specialized clinical supply schedules, which can introduce fluctuations not linked to broader business cycles. Sequential monthly evaluations offer the most direct read on operational velocity, though early estimates frequently undergo minor recalculations as complete industry panels report. While related to general chemical manufacturing, pharmaceutical production paths often decouple due to inelastic end-market demand and distinct regulatory constraints governing medical goods.
Frequently asked questions
- Does this index cover retail pharmacies and drug distribution?
- No, it is restricted to manufacturing establishments engaged in medicinal chemical synthesis and therapeutic product formulation.
- Why can month-to-month production display unusual lumpiness?
- Batch production cycles, regulatory compliance checks, and specialized pharmaceutical sterilisation schedules often cause discrete volume jumps.
- Is year-on-year comparison preferred over monthly tracking here?
- Sequential monthly tracking is generally more useful for spotting sudden manufacturing shifts, provided analysts account for regular regulatory review periods.